These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30690047)

  • 21. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
    Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
    J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
    [No Abstract]   [Full Text] [Related]  

  • 24. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
    Blauvelt A
    Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study.
    Georgakopoulos JR; Ighani A; Phung M; Yeung J
    J Am Acad Dermatol; 2018 May; 78(5):1019-1020. PubMed ID: 29180095
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
    Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
    Azevedo A; Torres T
    Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis.
    Dicaro D; Bowen C; Dalton SR
    J Am Acad Dermatol; 2014 Mar; 70(3):e64-5. PubMed ID: 24528921
    [No Abstract]   [Full Text] [Related]  

  • 29. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
    Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
    [No Abstract]   [Full Text] [Related]  

  • 30. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis.
    Wendling D; Letho-Gyselinck H; Guillot X; Prati C
    J Rheumatol; 2012 Mar; 39(3):657. PubMed ID: 22383356
    [No Abstract]   [Full Text] [Related]  

  • 31. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
    Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
    J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
    [No Abstract]   [Full Text] [Related]  

  • 32. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
    Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
    Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serious infections among a large cohort of subjects with systemically treated psoriasis.
    Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
    J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.
    Yamauchi PS; Bissonnette R; Teixeira HD; Valdecantos WC
    J Am Acad Dermatol; 2016 Sep; 75(3):612-618.e6. PubMed ID: 27061047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e338-e341. PubMed ID: 31001858
    [No Abstract]   [Full Text] [Related]  

  • 39. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission.
    Bellinato F; Girolomoni G; Gisondi P
    Br J Dermatol; 2019 Dec; 181(6):1319-1320. PubMed ID: 31209871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.